The transcript for Amgen Inc.'s fourth quarter and full-year 2012 financial results indicates several positive and stable aspects that are likely to have a positive short-term impact on the stock price.

### Key Points:
- **Strong Financial Performance**: Amgen reported an 11% increase in total revenues and a 22% increase in adjusted EPS for the full year 2012, driven by strong performance across its product portfolio[1][3].
- **Guidance and Outlook**: The company provided guidance for 2013, expecting revenue growth of 3-5% and adjusted EPS growth of 5-10%, which suggests continued growth and stability[3].
- **Pipeline Advancements**: Amgen highlighted significant advancements in its pipeline, including the initiation of Phase III studies for AMG 145 and the acquisition of deCODE Genetics, which enhances their capabilities in target identification and validation[3].
- **Capital Return**: Amgen has completed its $10 billion share repurchase program and plans to focus more on increasing dividends, with a 31% increase in the dividend for 2013. This indicates strong capital returns to shareholders[3].
- **Management Confidence**: The leadership team expressed confidence in navigating competitive and macroeconomic challenges, and in the long-term growth opportunities driven by their pipeline and strategic initiatives[3].

### Conclusion:
Given the strong financial performance, positive guidance, advancements in the pipeline, and robust capital return strategy, the stock is likely to experience a positive impact in the short term.

[1]